Jesy Nelson Reveals Twins’ Diagnosis of Spinal Muscular Atrophy

Jesy Nelson, former member of the pop group Little Mix, has publicly shared the heartbreaking diagnosis of her twin babies: they have been diagnosed with Spinal Muscular Atrophy (SMA), a rare genetic condition that will prevent them from walking. The announcement has drawn attention to this serious and complex disease, which affects motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy.

Understanding SMA is crucial, especially as it impacts numerous families worldwide. The primary symptom is muscle weakness, which typically begins in the muscles closest to the center of the body, including the shoulders, hips, and thighs. As the disease progresses, it can lead to several severe complications, such as respiratory issues, feeding difficulties, and scoliosis.

What Is Spinal Muscular Atrophy?

At its core, SMA results from a deficiency of a protein known as Survival Motor Neuron (SMN). This protein is essential for the health and survival of motor neurons, the nerve cells responsible for sending signals from the brain to the muscles. Individuals typically have two copies of the SMN1 gene that produces this vital protein. Those with SMA possess two altered or missing copies of the gene, resulting in insufficient SMN protein production. Consequently, motor neurons begin to deteriorate, leading to muscle atrophy.

SMA is classified into different types based on the age of onset and the highest physical milestone achieved. The most common form is Type 1 (Werdnig-Hoffmann Disease), typically diagnosed before six months of age. Infants with this type struggle to lift their heads, swallow, or breathe independently. Type 2 usually appears between 6 and 18 months, where children can sit up but cannot stand or walk without significant assistance. Type 3 (Kugelberg-Welander Syndrome) is diagnosed after 18 months, where children can walk but may face frequent falls. Finally, Type 4 is a rare adult-onset form that manifests after age 20 or 30, leading to mild to moderate muscle weakness.

Advancements in Treatment

For many years, a diagnosis of Type 1 SMA was considered a terminal prognosis, with affected children often not surviving past their second birthday. However, recent medical breakthroughs have dramatically changed the outlook for this condition.

Three treatments have emerged as pivotal in managing SMA. The first, Zolgensma, is a gene therapy administered as a one-time intravenous infusion that replaces the missing or non-functioning SMN1 gene. Another treatment, Spinraza (Nusinersen), is injected into the spinal fluid and assists the backup gene, SMN2, in producing more functional protein. Lastly, Evrysdi (Risdiplam) is a daily oral liquid that also targets the backup gene to enhance protein levels.

While these treatments do not cure SMA or reverse existing damage to motor neurons, they can halt disease progression and, if initiated early enough, enable children to achieve significant developmental milestones, such as sitting or walking.

Jesy Nelson’s courageous disclosure has not only highlighted the challenges faced by families coping with SMA but has also underscored the importance of ongoing research and advancements in treatment options. As awareness grows, so does hope for improved outcomes for those affected by this life-altering condition.